Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722987 | 0.80 | GAA (0.31) | GAAL3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL1701016 | 0.79 | GAA (0.35) | GAAL3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2585086 | 0.73 | GAA (0.36) | GAAL3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL1701141 | 0.71 | MAPT (0.37) | GAAL3MBTL1MAPT | |
| SCHEMBL724532 | 0.71 | GAA (0.31) | GAAMAPTSMN1; SMN2 | |
| SCHEMBL720448 | 0.70 | GAA (0.33) | GAAL3MBTL1MAPT | |
| SCHEMBL1701197 | 0.70 | GAA (0.33) | GAAL3MBTL1TP53MAPTSMN1; SMN2 | |
| SCHEMBL19914262 | 0.65 | L3MBTL1 (0.41) | GAAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL766778 | 0.64 | — | — | |
| SCHEMBL2592211 | 0.62 | MAPT (0.64) | TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885L3MBTL1 3943/4885TP53 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.